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Abstract (Italian) 
Introduzione: Lo scompenso acuto in cirrosi è definito come la progressione acuta di 
una o più gravi complicanze della patologia epatica ed è la principale causa di 
ospedalizzazione nei pazienti con cirrosi. L'insufficienza epatica acuta su cronica (ACLF) 
è caratterizzata da uno scompenso acuto della cirrosi, da danno d'organo e da un 
elevato tasso di mortalità a 28 giorni. L'ACLF è caratterizzato da infiammazione 
sistemica e l'outcome infausto è strettamente associato con l'eccessiva risposta 
infiammatoria che si attiva nel paziente. L'inflammasoma è un complesso multi-
proteico che attiva, mediante taglio proteolitico, citochine pro-infiammatorie come IL-
1β e IL-18. Queste, hanno un ruolo nello sviluppo della patologia epatica. Le vescicole 
extracellulari (EVs) sono coinvolte in molti processi biologici importanti, sia fisiologici 
che patologici. Il processo di secrezione delle EVs da diversi tipi di cellule e la loro 
azione nel modulare l'avanzamento della patogenesi nella malattia epatica, non sono 
ancora completamente chiariti. 
Scopo: Lo scopo di questo studio è caratterizzare la via del segnale coinvolta nello 
scompenso acuto della cirrosi e dell'insufficienza epatica acuta-su-cronica attraverso: 
la caratterizzazione del profilo infiammatorio dei pazienti arruolati, lo studio in vitro 
dell'effetto citotossico nel plasma dei pazienti nelle cellule tubulari renali (RTC), lo 
studio dell'espressione dell'inflammasoma nelle cellule trattate e nelle cellule 
mononucleate del sangue periferico (PBMC) estratte dai pazienti, la caratterizzazione 
delle EVs estratte dal plasma dei pazienti arruolati e lo studio del loro effetto in vitro su 
colture di RTC. 
Materiali e Metodi: sono stati arruolati pazienti con cirrosi compensata, scompenso 
acuto in cirrosi, insufficienza epatica acuta-su-cronica e una popolazione di volontari 
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sani come controllo. I livelli plasmatici di IL-6, IL-1β e IL-18 sono stati misurati con kit 
ELISA. L'effetto citotossico del plasma nelle RTC è stato testato con il kit costituito da 
annexina V e propidio ioduro. Il livello di espressione delle molecole 
dell'inflammasoma è stato determinato sia nelle cellule stimolate con il plasma, sia nei 
PBMC estratti dai pazienti, attraverso Real Time Poly Chain Reaction (RT-PCR). Le EVs 
plasmatiche sono state estratte mediante ultracentrifugazione e la loro concentrazione 
determinata con il Nanosight. La loro caratterizzazione è stata eseguita mediante 
analisi al FACS. L'effetto citotossico delle EVs sulle RTC è stato determinato mediante 
saggio XTT. 
Risultati: I livelli plasmatici delle citochine pro-infiammatorie, misurati nei primi 
pazienti arruolati, non mostra differenze tra i gruppi di pazienti con cirrosi 
compensata, scompensata e insufficienza epatica acuta-su-cronica. Anche la vitalità e 
la morte cellulare nelle colture stimolate con i plasma dei pazienti arruolati non hanno 
mostrato un profilo peculiare dei gruppi testati e non è stata riscontrata attivazione 
della trascrizione delle molecole dell'inflammasoma. L'espressione del Tool-like 
receptor 2 (TLR-2) nei PBMC si è dimostrata significativamente elevata nei pazienti con 
cirrosi compensata rispetto a quelli con scompenso acuto (p=0,036). Aggiungendo 
albumina al mezzo di coltura cellulare si è notata una riduzione dell'effetto citotossico 
del plasma dei pazienti nelle RTC. La concentrazione plasmatica di EVs risulta maggiore 
nei pazienti con insufficienza epatica acuta-su-cronica rispetto ai controlli sani. Le 
vescicole non esprimono i marcatori tipici piastrinici (CD41 e CD42b) e monocitari 
(CD14) sulla loro superficie ma esprimono il marcatore dell'epitelio attivato da 
piastrine (CD62E). I livelli di CD62E sono significativamente elevati nei pazienti con 
insufficienza eparica acuta-su-cronica rispetto ai controlli sani e ai pazienti con cirrosi 
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compensata (p=0,0041 e p=0,0111, rispettivamente). I livelli di CD40L sono 
significativamente elevati in tutti i gruppi di pazienti rispetto ai controlli sani (p<0,02). 
Le EVs isolate dei pazienti con insufficienza epatica acuta-su-cronica hanno un effetto 
citotossico superiore rispetto a quelle dei controlli sani e dei pazienti con cirrosi 
compensata nelle RTC (p<0,0001). Le cellule incubate con le EVs da pazienti con 
scompenso acuto in cirrosi e insufficienza epatica acuta-su-cronica vanno incontro ad 
apoptosi (p<0,0001), a produzione massiccia di ROS (p<0,0001), alla perdita della 
capacità di  internalizzare l'albumina (p<0,0001) e alla riduzione dell'espressione di 
Zonula Occludens-1 (ZO-1) (p=0,0166) rispetto ai soggetti sani e ai pazienti con cirrosi 
compensata. Non si osserva invece un cambiamento nell'espressione cellulare di 
megalina e PGC1α.  
Conclusioni: Il ruolo delle EVs nella cirrosi scompensata necessita di essere 
approfondito perché potrebbero rappresentare il veicolo su cui viaggiano i mediatori 
del danno d’organo extraepatico. 
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ABSTRACT (English) 
Introduction: Acute decompensation was defined as the acute development of one or 
more major complications of liver disease and it was the main cause of hospitalization 
in patients with cirrhosis. The acute-on-chronic liver failure (ACLF) was characterized 
by acute decompensation of cirrhosis, organ failure and high 28-day mortality. ACLF 
displayed key features of systemic inflammation and its poor outcome was closely 
associated with exacerbated systemic inflammatory responses. Inflammasomes were 
multiprotein complexes which proteolytically activates the cytokines IL-1β and IL-18. 
These substrates might have an effect on the development of liver disease. 
Extracellular vesicles (EVs) were involved in many important biological processes as 
well as in disease pathogenesis. The dynamics of EVs secretion by different cell types 
and how the secreted EVs interact to advance the pathogenesis of liver disease were 
still unknown.  
Aims: The aim of this study was to characterize the molecular pathways involved in 
acute decompensation of cirrhosis and ACLF through: the characterization of the 
inflammatory profile of patients, the in vitro evaluation of cytotoxic effects of plasma 
from patients on renal tubular cells, the expression of Inflammasome in these treated 
cells and in Peripheral Blood Mononuclear Cells (PBMC) of patients, the 
characterization of EVs from patients and the study of in vitro effects of isolated EVs in 
renal tubular cells. 
Material and Methods: We enrolled patients with compensated cirrhosis, acute 
decompensation in cirrhosis, ACLF and healthy subjects as control population. Plasma 
levels of IL-6, IL-1β and IL-18 were detected by ELISA assay. Cytotoxic effects of plasma 
on renal tubular cells were assayed by annexin V and propidium iodide kit. 
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Inflammasomes expression was detected both in renal tubular cells treated and in 
PBMC extracted from patients by Real Time PCR. Plasma EVs were extracted by 
ultracentrifugation and concentration was measured by Nanosight. Characterization of 
EVs was performed by FACS analysis. Cytotoxic effects of plasma EVs on renal tubular 
cells were assayed by XTT assay. 
Results: Plasma levels of pro-inflammatory cytokines measure in the firsts patients 
enrolled did not differed between the groups of compensated cirrhosis, acute 
decompensation and ACLF. Also viability and death rate did not change in a way 
statistically significant in cell stimulated with plasma from the three groups of patients. 
Furthermore, Inflammasome gene expression in these cells did not underlines the 
activation of this protein complex. In PBMC from patients, gene  expression of Tool-like 
receptor 2 (TLR-2) was significantly higher in patients with compensated cirrhosis 
compare to acute decompensation of cirrhosis (p=0.036). Albumin added to cell 
medium reduced cytotoxic effects of plasma on renal tubular cells. Plasma EVs of 
patients enrolled were more concentrated in ACLF groups compare to healthy subjects. 
EVs did not expressed selected platelets (CD41, CD42b) and monocyte markers (CD14) 
in their surface but they expressed marker of platelets  activated endothelium (CD62E). 
The levels of CD62E were significantly higher in patients with ACLF compare to healthy 
subjects and patients with compensated cirrhosis (p=0.0041 and p=0.0111, 
respectively). CD40L levels were significantly higher in all patients' groups compare to 
healthy subjects (p<0.02). Plasma EVs from patients with acute and acute-on-chronic 
liver failure exerted a higher cytotoxic effects compare to healthy subjects and patients 
with compensated cirrhosis on renal tubular cells (p<0.0001). Cells incubated with EVs 
from acute and acute-on-chronic liver failure underwent to apoptosis (p<0.0001), to 
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ROS production (p<0.0001), to lose albumin intake capabilities (p<0.0001) and 
reduction of Zonula Occludens-1 (ZO-1) expression (p=0.0166) compare to healthy 
subjects and patients with compensated cirrhosis. Instead, megalin and PGC1α 
expression did not change. 
Conclusions:  The role of EVs in decompensated cirrhosis and ACLF need to be 
invastigated and study their hypothetic role as vehicle of mediator of extrahepatic 
organ injury and complications of cirrhosis. 
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Introduction 
1 Inflammatory response in Acute decompensation and Acute-on-
chronic liver failure 
Liver cirrhosis is the most advanced stage of chronic liver disease and represents a 
leading cause of mortality in adults, resulting in 1.03 million deaths per year worldwide 
(1). For several years cirrhosis has been considered a progressive disease characterized 
by a compensated phase followed by a decompensated phase and resulting invariable 
in death. In the last 20 years, with the development of effective etiological treatments, 
this concept has been overcome and cirrhosis has been considered a dynamic disease 
across compensated and decompensated stages (1). More recently, with the discovery 
of acute-on-chronic liver failure (ACLF) these concepts have been further revised. 
Indeed, it has been shown that in any stages of the disease an acute decompensating 
event may occur, leading to organ failure and conferring a high mortality risk (2). 
Definitions and outcomes 
Acute decompensation is defined as the acute development of one or more major 
complications of liver disease (ie, ascites, encephalopathy, gastrointestinal 
hemorrhage, bacterial infection), and it is the main cause of hospitalization in patients 
with cirrhosis (3).  
According to the European Association for the Study of the Liver Chronic Liver Failure 
(EASL-CLIF) consortium ACLF is characterized by 3 main features: presence of acute 
decompensation, organ failure (predefined by the SOFA-CLIF score) and high 28-day 
mortality rate (threshold of 15%) (4). 
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The Sequential Organ Failure Assessment (SOFA) scale which is used to diagnose organ 
dysfunctions and failures in general intensive care units (ICUs) (5). The SOFA score was 
found to be a better predictor of short-term prognosis of patients with cirrhosis than 
were liver-specific scores (the Child-Pugh and MELD scores). The investigators of the 
CANONIC study (4) used a modified SOFA scale, called CLIF-SOFA (Table 1). The CLIF-
SOFA scale assessed the function of six organ-systems (liver, kidneys, brain, 
coagulation, circulation, and respiration) but also included some markers specific for 
cirrhosis. The definitions for organ failures based on the CLIF-SOFA scale were as 
follows: 1) Liver failure was defined by serum bilirubin levels of 12.0 mg/dL or more; 2) 
Kidney failure was defined by serum creatinine levels of 2.0 mg/dL or more, or the use 
of renal-replacement therapy; 3) Cerebral failure was defined by grade III or IV hepatic 
encephalopathy according to the West Haven classification; 4) Coagulation failure was 
defined by an International Normalized Ratio (INR) of more than 2.5 and/or platelet 
count of 20×109/L or less; 5) Circulatory failure was defined by the use of vasopressin 
(including terlipressin) to maintain arterial pressure; 6) Respiratory failure was defined 
by a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (FiO2) of 
200 or less or a pulse oximetry saturation (SpO2) to FiO2 ratio of 200 or less (Table 1). 
ACLF has been graded in 3 stages: 
Stage 1: Patients with serum creatinine (sCr) ≥ 2 mg/dl; patients with single failure of 
the liver, coagulation, circulation, or respiration who had a sCr level ranging from 1.5 
to 1.9 mg/dL and/or mild to moderate hepatic encephalopathy (grade 1 or 2 according 
to West Haven criteria); and patients with single cerebral failure who had a serum 
creatinine level ranging from 1.5 and 1.9 mg/dL; 
Stage 2: Patients with 2 organ failures; 
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Stage 3: Patients with 3 organ failures or more. 
About 31% of patients with an acute decompensation of cirrhosis develop ACLF during 
the hospitalization. The occurrence of ACLF confers high risk of mortality, being 33% 
and 51% at 28-days and 90 days, respectively (4). Conversely, the prognosis of patients 
with an acute decompensation of cirrhosis without ACLF are quite better, being 2% 
and 10% at 28-days and 90-days, respectively. Finally, a stepwise increase in mortality 
rate has been found according to ACLF staging (23% for stage 1, 31% for stage 2 and 
75% for stage 3 at 28 days).  
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Table 1: The Chronic Liver Failure (CLIF)-Sequential Organ Failure assessment (SOFA) Scale*  
(Moreau R., Clin Mol Hepatol. 2016; 22(1): 1–6) 
 
Organ/system 
Score 
0 1 2 3 4 
Liver; Bilirubin, mg/dL 
<1.2 ≥1.2 - <2.0 ≥2.0 - <6.0 ≥6.0 - <12.0 ≥12.0 
Kidney; Creatinine, 
mg/dL 
<1.2 ≥1.2 - <2.0 ≥2.0 - <3.5 ≥3.5 - <5.0 ≥5.0 
  
  
or use of renal-replacement therapy 
Cerebral; HE grade† No HE I II III IV 
Coagulation; INR‡ 
<1.1 
≥1.1 - 
<1.25 
≥1.25 - <1.5 ≥1.5 - <2.5 
≥2.5 or Platelets 
≥20×109/L 
Circulation; MAP 
mmHg ≥70 <70 
Dopamine ≤5 or 
Dobutamine or 
Terlipressin§ 
Dopamine >5 or E 
≤0.1 or NE ≤0.1 
Dopamine >15 or E 
> 0.1 or NE > 0.1 
Lungs; PaO2/FiO2: or 
>400 
>300 - 
≤400 
>200 - ≤300 >100 - ≤200 ≤100 
SpO2/FiO2Π 
>512 
>357 - 
≤512 
>214 - ≤357 >89 - ≤214 ≤89 
 
HE denotes hepatic encephalopathy; INR, International Normalized Ratio; MAP, mean arterial pressure; E, epinephrine; NE, 
norepinephrine; PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen; SpO2, pulse oximetry saturation. 
*Adapted from ref. 1. The highlighted area in violet depicts the diagnostic criteria for organ failures. 
 †The CLIF-SOFA scale used West Have classification while the original SOFA scale used the Coma Glasgow score. 
 ‡INR was not included in the original SOFA scale. 
  §Terlipressin use was not taken into account in the original SOFA scale; doses for E and NE are expressed in 
μg/kg.min. 
 ΠThe SpO2/FiO2 ratio was not included in the original SOFA scale. 
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Multiorgan dysfunction and failure likely result from a complex interplay where the 
systemic spread of bacterial products represents the primary event. The consequent 
activation of the host innate immune response triggers endothelial molecular 
mechanisms responsible for arterial vasodilation, and also jeopardizes organ integrity 
with a storm of pro-inflammatory cytokines and reactive oxygen and nitrogen species. 
Thus, the picture of advanced cirrhosis could be seen as the result of an inflammatory 
syndrome in contradiction with a simple hemodynamic disturbance (6). 
Pathological bacterial translocation 
Bacterial translocation was defined as translocation of bacteria and/or bacterial 
products (lipopolysaccharides, peptidoglycans, muramyl-dipeptides, bacterial DNA, 
etc.) from the gut to mesenteric lymph nodes (7). It was a physiological process in 
healthy conditions and crucial for host immunity. In contrast, in cirrhosis, 
‘‘pathological’’ bacterial translocation developed with a sustained increase in quantity 
(rate and/or degree) of translocated bacteria (8). 
The most evidenced clinical expression of pathological bacterial translocation was 
spontaneous bacterial peritonitis (SBP). SBP often originates from bacteria in the gut 
that belong to the normal intestinal microbiota. In vivo experiments showed that E. coli 
administered orally to cirrhotic rats was found not only in the intestinal lumen but also 
in the mesenteric lymph nodes and ascites (9). Furthermore, not only bacteremia but 
also inflow of translocating bacterial products into the hepato-splancnic and systemic 
circulation impacted on the cirrhotic host (10). Three were the main routes of bacterial 
translocation: (1) direct sampling of luminal bacteria by dendritic cells via processes 
between epithelial cells, not affecting tight junction function; (2) injured/inflamed 
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epithelium with dysfunctional epithelial barrer; (3) M-cells overlaying Peyer Patches as 
specialized cells providing access of microbial products to antigen-presenting cells 
(Figure 1). 
Figure 1: Compartments and key players involved in mediating pathological bacterial translocation and 
the associated host response (Wiest R et al., J Hepatol. 2014;60(1):197-209). 
 
 
One more time, three different levels of barrier against bacterial translocation were 
known (I-III, Figure 1): (I) lumen and secretory component (mucus layer, antimicrobial 
peptides) of gut barrier; (II) mechanical epithelial barrier and the gut-assiciated 
lymphatic tissue (GALT) beneath with response elements to bacterial translocation 
(pro-inflammatory cytokines) and autonomic nervous system; (III) systemic immune 
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system in case of spreasing of bacterial beyond mesenteric lymph nodes including 
hematogenous (portal venous) and lymphatic (ductus thoracicus) route of delivery 
(11). Rate and degree of pathological bacterial translocation increased with severity of 
liver disease: whereas they were increased in early cirrhosis, pathological translocation 
of viable bacteria occurs in the decompensated stage. Influencing factors that impact 
on the compartments driving pathological bacterial translocation were multiple and 
key players were pro-inflammatory cytokines, malnutrition (12), sympsthetic 
hyperactivity (13), genetic susceptibility (14, 15) and lack of bile acids (16, 17). After a 
priming events of paracellular translocation of bacterial products in early stage of 
cirrhosis, the main hypothesis was that epithelial tolerance, that normally avoids 
overwhelming mucosal inflammation, enhanced transcytosis of viable bacteria leading 
to immune paralysis in the GALT (18, 19). Augmented pro-inflammatory response to 
gut-derived products and failure to control invading bacteria and -products in concert 
with host susceptibility determined remote organ injury. This may included acute-on-
chronic liver failure, hepato-renal-syndrome and hepatic encephalopathy (10). 
Therefore, understanding the physiology of gut-bacteria interactions and the 
pathogenesis of bacterial translocation can lead to new therapeutic targets in the 
prevention of infections and other complications of cirrhosis. 
Pathogenesis 
The pathogenesis of acute-on-chronic liver failure is still debated, however, the 
common denominator seems to be the systemic inflammation (4). Indeed, white cell 
count and plasma C-reactive protein levels were found to be higher in patients with 
acute-on-chronic liver failure than those with acute decompensation. Similar findings 
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were found for plasma levels of several cytokines (for example: IL-6, TNF-α) and 
chemokines (IL-8) (20). Therefore, acute-on-chronic liver failure is characterized by an 
excessive inflammatory response during the "early ACLF" (2). 
The inflammatory response can be triggered from so-called inducers, that can be 
exogenous (microbial and nonmicrobial) and endogenous, such as signals released 
from necrotic cells or products of extracellular matrix breakdown (21).  
Exogenous inducers  
Bacterial infections have been considered to be a relevant trigger of ACLF. Indeed, 
almost 30% of cases of ACLF a bacterial infection can be identified as a potential 
precipitating event. Bacterial inducers are pathogen-associated molecular patterns 
(PAMPs) and virulence factors (21). PAMPS are recognize by pattern-recognition 
receptor (PRRs), which are receptors of host innate immune system and include toll-
like receptors (TLRs), nucleotide-binding oligomerization domain- (NOD-) like receptors 
(NLRs), retinoic acid-inducible gene- (RIG-), cytosolic DNA sensors. PRRs may be 
localized in cell surface or in the endolysosome compartment such as TLRs, or they 
may be cytosolic receptors such as NLRs, RIG-I and DNA sensors. When PAMPs bind 
PRRs, they trigger a signaling cascades that activate transcription factors. These last 
increase the transcription of antimicrobial effectors gene, cytokines and chemokines 
genes and other molecules of adaptive immunity (21, 22). When bacteria invade host 
cells, they may be recognized and bound by intracellular PRRs. 
After binding of PAMPs, PRRs assemble into high-molecular weight, caspase-1-
activating platforms called ‘‘inflammasomes’’ that control maturation and secretion of 
interleukins such as IL-1β and IL-18, whose potent pro-inflammatory activities direct 
host responses to infection and injury (23). 
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Inflammasomes 
Inflammasomes are platforms for Caspase-1 activation and IL-1β maturation (23). 
Caspases are cysteine proteases involved in inflammation and cell death. Their potent 
cellular activities are controlled by proteolytic activation. Caspase-1 is a pro-
inflammatory caspase whose catalytic activity is tightly regulated by signal-dependent 
autoactivation whithin inflammasomes (24). IL-1β is a pro-inflammatory mediator 
generated in the site of injury and it is involved in cellular recruitment to a site of 
infection or injury. Pro-inflammatory stimuli induce expression of the inactive IL-1β 
proform, but cytokine maturation and release are controlled by inflammasomes. 
Inflammasomes are assembled by self-oligomerizing scaffold proteins. NLR family 
member showed inflammasome activity in vitro. In fact, NLRP3 inflammasome is 
currently the most fully characterized inflammasome and consist of the NLRP3 
scaffold, the ASC (PYCARD) adaptor, and Caspase-1 (23). 
Upon NLRP3 activation, NLRP3 oligomerization leads to PYD domain clustering and 
presentation for homotypic interaction with the PYD- and CARD-containing the 
adaptor ASC, whose CARD domain in turn recruits the CARD of procaspase-1. 
Procaspase-1 clustering permits autocleavage and formation of Caspase-1, which then 
processes cytokine maturation and secretion of pro-inflammatory cytokines, such as 
interleukin-1β and IL-18 (23)(Figure 2).  
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Figure 2: NLRP3 Inflammasome Activation (Schroder K. et al. Cell 2010 (140):821-832).  
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Endogenous inducers 
Endogenous inducers are produced from tissue damage or injury. They are molecules 
released by necrotic cells and product of breakdown of the extracellular matrix. They 
are called danger-associated molecular patterns (DAMPs) and they are recognized by 
sensor expressed at the surface of resident macrophages and trigger inflammation 
(25). Necrosis can be result of the induction of programmed cell death, and in this case 
includes processes of pyroptosis and necroptosis. Only pyroptosis results from 
inflammasome activation (26).  
Necrotic cells release adenosine triphosphate (ATP) that can be binded from PRRs and 
contribute to NLRP3 inflammasome activation in macrophages (22). 
Immunopatology and Outcomes 
The aim of the inflammatory response to bacterial infection is to promote host 
resistance by reducing bacterial burden, instead the aim of the DAMPs-mediated 
response to tissue injury is to promote tissue repair (26). Both the two categories of 
inflammatory response, when excessive, may induce tissue damage. The excessive 
inflammatory response to bacterial infection that cause collateral tissue damage is a 
process called immunopathology. Bacterial are potential causes of immunopathology, 
but they can exert tissue damage also via toxins and virulence factors (21, 26). Severe 
outcome of bacterial infection can be caused by failure of protective tissue-intrinsic 
mechanisms. Several studies report that severity of the disease may be related to 
failed disease tolerance (27-29). 
Immunopatology is a major mechanism explaining the development of ACLF in 
patients with SBP. SBP caused by gram-negative bacteria of intestinal origin is the most 
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common infection in patients with cirrhosis, and it is more common in patients with 
ALCF than in those without (4). In case of SBP, the greater the intensity of the immune 
response, the higher the risk of developing Hepatorenal Syndrome Type 1, a form of 
ACLF (30). 
Immune response is in general dependent from age and from genetic factors. Patients 
with ACLF are younger than those without (4) and show a more vigorous immune 
response to infection (27). Regarding genetics factors, it was demonstrated that 
variants of cytosolic receptor NOD2 may contribute to susceptibility to intestinal 
bacterial translocation, in a manner NFkB dependent (15), and to the poor outcome of 
patients. Single-nucleotide polymorphism (SNPs) in gene encoding PRRs (TLR2, TLR4) 
or nuclear receptor are associated with an increased risk of bacterial infection in 
patients with cirrhosis (31). Recently, Alcaraz-Quiles J. et al. identify two common 
functional polymorphisms in the IL-1 gene cluster (rs1143623 in IL-1β gene and 
rs425196 in IL-1ra) which are associated with the inflammatory process related to the 
development of ACLF (32). 
 Almost 20% of the cases of ACLF are precipitated by alcohol consumption and in some 
cases may have the characteristic of alcoholic hepatitis (4). The main features of 
alcoholic hepatitis are hepatocyte death and liver inflammation, with prominent 
neutrophil infiltration (33). 
Patients with excessive alcohol consumption have gut dysbiosis and increase of 
permeability of intestinal barrier (11, 33). As a consequence, translocation of bacterial 
PAMPs may occur. PAMPS were recognized and binded by TLRs in liver resident 
macrophages. This binding to TLRs stimulates the production of pro-inflammatory 
cytokines that are potent neutrophil-attracting cues. Therefore, on the one hand, 
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production of pro-inflammatory cytokines and mediators can lead to tissue damage, 
on the other hand there are findings suggesting that the primary purpose of 
inflammatory response might be to promote tissue repair/regeneration. In fact, it has 
been observed a better prognosis the higher is the liver infiltration by neutrophils (34). 
Activity of TNF-α, induced by lipopolysaccharide (LPS) of gram-negative bacteria, 
stimulate production of reactive oxygen species (ROS) from hepatocytes and so 
oxidative stress (33). Subsequently, ROS and LPS induce hepatocyte endoplasmatic 
reticulum stress, that together with oxidative stress trigger a cell-extrinsic response 
that contains homeostasis-restoring components (35). Patients with severe alcoholic 
hepatitis also develop extrahepatic organ failures but it is still unclear whether an 
excessive systemic inflammatory response can lead to extrahepatic organ failure. 
At last, approximately 50% of cases of ACLF is of unknown origin, but probably they are 
associated with systemic inflammation (4). Three hypotheses have been proposed: the 
presence of gut dysbiosis, the role of translocation of bacterial PAMPs and the action 
of endogenous inducers of inflammation (as shown above). 
In patients with gut dysbiosis, it was shown a decrease of Bacteroidaceae and an 
increase of Enterobacteriaceae, but this is dependent from stage of cirrhosis and its 
severity (36-40). However, changes in gut microbiome correlates with a more intense 
systemic inflammation, probably due to metabolites produced by intestinal 
microbiome itself (40). 
About bacterial translocation, it was shown that bacteria could release PAMPs that 
reach systemic circulation, it can be recognized by TLRs at different sites and trigger 
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inflammation (41, 42). Generally, TLR recognition is not dependent on bacteria viability 
or invasiveness (26). 
Among ACLF patients, indipendently from levels of systemic inflammation, patients 
who have prior episodes of decompensation of liver disease have a lower risk of death 
than those who do not have prior episodes of decompensation (4). It has been 
hypothesized that patients may be primed by prior episodes of decompensation and 
become more tolerant when exposed to new noxious stimuli.  
An extreme inflammatory response is not the only feature of ACLF. Interestingly it has 
been shown that in patients with ACLF circulating CD14+ immune cells are enriched 
MER-expressing subset of cells which exhibit decreased responses to LPS stimulation. 
MER receptor have a role in the clearance of apoptotic cells by phagocytes and it is the 
expression product of MERTK gene. The induction of MERTK occurs in response to 
stimuli homeostatic-restoring signals (43). Therefore, CD14+ cells expressing MER 
receptor may be engaged to protect damage tissues in ACLF contest.  
Further stressing these concepts it has been shown that plasma from patients with 
acute decompensation had increased levels of prostaglandin E2 that may inhibit the 
macrophages TNF-α production in response to LPS (44) and decrease the macrophages 
ability to kill bacteria.  
This findings suggests that some patients with ACLF and acute decompensation of 
cirrhosis show an immuneparalysis that may confer a predisposition to the 
development of new infections, that impairs survival in patients with cirrhosis (45). In 
patients with ACLF it may represent a sort of compensatory anti inflammatory 
response that is a well known condition in patients with sepsis (46). 
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2 Organ crosstalk 
The human organism is organized in various organ systems that are intimately 
connected to each other. The concept of “crosstalk” has not been clearly defined . The 
term comes from electronics, denoting any signal or circuit that unintentionally affects 
another. In molecular biology, crosstalk is used to describe instances when one or 
more components of signal transduction pathway affect a different pathway, either at 
the transmembrane or at the intracellular level. The “organ crosstalk” can be defined 
as the complex biological communication, signaling and feedback between distant 
organs mediated via cellular, molecular, neural, endocrine and paracrine factors. The 
physiological crosstalk is necessary to maintain regular homeostasis and normal 
functioning of the organism. Nevertheless, a pathological crosstalk can also develop 
when the effect of one malfunctioning and damage organ induces structural and/or 
functional dysfunction in distant organs. This effect is usually negative since it results 
injurious and destructive for the target organs and, as consequence, for the whole 
organism (47-50). Thus, in the diseased state, the crosstalk can trigger an organ 
disequilibrium and create a vicious damage in distant organs (49, 50).  
Liver and Kidney crosstalk 
Liver and kidney are important regulators of body homeostasis and are involved in 
excreting the toxic byproducts of metabolism and exogenous drugs (51). The 
intersection of liver and kidney disorders is so frequent in clinical practice that it 
seemed likely the hypothesis of a bidirectional crosstalk. There are a number of 
potential contributing causes for liver-kidney crosstalk that may predispose to the 
development of this vicious interaction and which are relevant for the susceptibility, 
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etiology, severity and duration of the disease state. Severity of the failing organ can 
initiate various complex metabolic, cell mediated and humoral pathways affecting 
distant organs, contributing to the high therapeutic costs, and significantly higher 
morbidity and mortality. The severity of liver damage often parallels the severity of 
kidney injury and viceversa (51, 52). An acute kidney injury (AKI) is common in patients 
with a severe liver disease while AKI may per se induce a liver damage by promoting 
oxidative stress, inflammation and apoptosis.  
IgA Nephropathy and Hepatorenal Syndrome are examples of pathological crosstalk. A 
high incidence of IgA nephropathy has been reported in patients with liver cirrhosis, 
though, clinically evident nephrotic syndrome is very uncommon. Impaired hepatic 
clearance of circulating IgA immune complexes and subsequent deposition in renal 
glomeruli has been considered principally in the pathogenesis of liver cirrhosis 
associated IgA nephropathy (53). Hepatorenal syndrome (HRS) is a functional form of 
acute kidney injury (AKI) that develops in patients with advanced cirrhosis or fulminant 
hepatic failure. It is the cause of deterioration of kidney function in only a fraction of 
all AKI cases diagnosed in cirrhotic patients (54). 
The liver-kidney crosstalk in the disease state is poorly understood. A better 
understanding of this bidirectional crosstalk may offer improved management 
strategies but it encompasses several mechanisms of cell and tissue damage and/or 
dysfunction.  
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3 Extracellular vesicles 
Several mechanisms involved in cell-to cell communication have been identified, 
including secretion of growth factors, cytokines, surface receptors, and nucleotides. 
Recent studies have suggested that cells may also communicate by membrane-derived 
nanometer-sized vesicles termed Extracellular Vesicles (EVs). For a long time, EVs were 
considered to be inert cellular debris and the frequently observed vesicles by electron 
microscopy in the interstitial space of tissues or in blood were considered the 
consequence of cell damage or the result of dynamic plasma membrane turnover. EVs 
are released by normal and diseased cells, both in vitro and in vivo. They have been 
identified in all major bodily fluid, including blood, urine, bile, saliva, semen, 
cerebrospinal fluid, as well as in cirrhosis-associated ascites (55). EVs are involved in 
many important biological processes as well as in disease pathogenesis (56, 57). EVs 
represent an heterogeneous population, differing in cellular origin, number, size, 
antigenic composition, and functional properties. 
Classification of EVs 
Based on their cellular biogenesis, EVs are classified into three groups: exosomes, 
microvesicles and apoptotic bodies (58). Exosomes are EVs derived from intracellular 
trafficking via the endolysosomal pathway: they are intraluminal vesicles contained in 
multivesicular bodies (MVBs), which are released to the extracellular environment 
upon fusion of MVBs with the plasma membrane. The size of exosomes is estimated to 
range between 40 and 150 nm in diameter (59). Microvesicles are vesicles of different 
sizes (usually from 50 to 1000 nm in diameter) which bud directly from the plasma 
membrane. Lastly, apoptotic bodies, usually greater than 500 nm in diamater, 
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represent cell fragments and they are formed by large-scale plasma membrane 
blebbing  during apoptosis. 
Communications via EVs 
The most critical function of EVs is intercellular communication. This may be paracrine, 
endocrine, and also autocrine. Communication via EVs involves two facets: target cell 
recognition and signal transfer to the target cell (60).  
EVs released from a given cell type may interact through specific receptor ligands with 
other cells, leading to target cell stimulation directly or by transferring surface 
receptors.  
This implicates that MVs interact only with target cells that specifically recognize 
rather than just with any cell present in the microenvironment. This interaction may 
either be limited to a receptor-mediated binding to the surface of target cells forming 
a platform for assembly of multimolecular complexes or leading to cell signaling, either 
to be followed by internalization as a result of direct fusion or endocytic uptake by 
target cells.  
Once internalized, MVs can fuse their membranes with those of endosomes, thus 
leading to a horizontal transfer of their content (mRNAs, microRNAs and proteins) in 
the cytosol of target cells. Alternatively, they may remain segregated within 
endosomes and be transferred to lysosomes or dismissed by the cells following the 
fusion with the plasma membrane, thus leading to a process of transcytosis. 
Several studies have demonstrated that RNA, DNA, and proteins are encapsulated in 
EVs as bioactive molecules. These play important role in intercellular communication, 
and in specific signal transduction in the pathophysiological states of cells both in vitro 
and in vivo (61-63).  
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In patients suffering from inflammation evoked by various diseases, EVs are often 
observed in plasma and in other body fluids (64-67) and the number of EVs are 
increased in response to the disease severity. In particular, the number of EVs has 
been observed to increase in the bloodstream of patients suffering from acute and 
chronic inflammation evoked by diseases such as sepsis, stroke, preeclampsia, 
atherosclerosis, diabetes mellitus, metabolic syndrome, and cancer (65, 67-71). 
Moreover, Hergenreider E. and Yamamoto S. (63, 72) showed that cells under 
inflammatory conditions actively communicate with their adjacent cells through EVs. 
Biological activities of  EVs 
EVs exert their effects on fundamental biological processes in a pleiotropic manner, 
directly activating cell surface receptors via protein and bioactive lipid ligands, merging 
their membrane contents into the recipient cell plasma membrane and delivering 
effectors including transcription factors, oncogenes, small and large non-coding 
regulatory RNAs, mRNAs and infectious particles into recipient cells (73-75)(Figure 3). 
 Manteinence of normal physiology: stem cell mainteinance, tissue repair, 
immune sorveillance and blood coagulation (64, 76); 
 Signalosomes: EVs can act as multifunctional signalling complexes for 
controlling fundamental cellular and biological functions (in the regulation of 
immune responses (77), in immune suppression (78) and immune activation 
(79); 
 Cell phenotype modulation: for example, in converting the hematopoietic stem 
cell phenotype into a liver cell phenotype (80); 
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 Stem cell maintenance and plasticity: stem cell-derived EVs have a pivotal role 
in tissue regeneration following injury (81); 
Pathological role of EVs 
 Stimulation of tumour progression: EVs induce proliferation in cells, stimulating 
tumor grown, stimulating angiogenesis, promoting matrix remodeling and 
inducing metastasis (75, 82); 
 Spread of pathogens: HIV-1, Epstein-Barr virus and prions (83-85); 
 Local propagation of neurodegenerative disease: Alzheimer Disease (86) and 
Parkinson's Disease (87). 
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Figure 3: Role of extracellular vesicles in normal physiology and disease pathogenesis (Nature Reviews 
Drug Discovery 12, 347-357 (2013)) 
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EVs in liver disease 
As it happens for cardiovascular disorders, thrombosis and cancer, also in case of liver 
cirrhosis circulating levels of EVs are increased. Some studies described this 
phenomena as a result of increased formation and/or decreased clearance of EVs. 
Causes which trigger EVs production are: alcohol consumption (88), viral infection (89), 
diabetes (90), obesity (91), dyslipidaemia (92) and physical inactivity (93). Processes in 
liver disease that increase EVs formation are apoptosis and cell activation. Moreover, 
stimuli for EVs release are oxidative stress (94), shear stress (95), systemic 
inflammation and bacterial translocation (96, 97). 
Under healthy conditions, spleen and liver macrophages are the primary contributors 
to EVs clearance from the circulation (98). It is well known that cirrhosis is associated 
with a defect in macrophage function, so Lemoinne S. et al. (99) speculate that 
clearance of EVs might be decreased in these patients. 
EVs in liver disease progression 
In physiological condition, extracellular vesicles are released at low levels from almost 
all cell types. Most of them are derived from platelets and endothelial cells (100) and 
have been shown to be important in haemostatic events such as coagulation. 
Nevertheless, the dynamics of EV secretion by different cell types and how the 
secreted EVs interact to advance the pathogenesis of a given disease is still unknown. 
Controlled in vitro study which involved liver injury model to explore EV-mediator 
fibrosis (101-103), transcriptomic signaling (104-108) and targeted immunotherapy 
(109-111) in artificial cell culture system. However, in vivo studies present an added 
degree of complexity due to the difficulty of identifying liver specific EVs within the 
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circulating pool. For this reason, several studies focus on EVs characterization and 
temporal changes in relation to liver disease development (112-114). 
Role of EVs in liver fibrogenesis, portal hypertension and activation of coagulation 
In hepatic fibrosis the excessive extracellular matrix is produced by activated 
mesenchymal cells which resemble myofibroblasts. They derive from quiescent hepatic 
stellate cells (115). It was shown that the same cells that drive fibrogenesis (hepatic 
stellate cells) can become major effectors of fibrolysis via production and activation of 
certain matrix metalloproteinases (MMPs) (116). Kornek et al. (103) demonstrated that 
T cell EVs circulate in blood and are elevated in patients with active chronic hepatitis C 
compared with patients with mild hepatitis C and healthy controls. Further, EVs 
derived both from CD8+ and CD4+ T cells can induce a fibrolytic phenotype in hepatic 
stellate cells. This activity depends on fusion of the plasmatic membrane with hepatic 
stellate cells membranes and transfer of T cell membrane molecules such as CD147  to 
hepatic stellate cells in a partly CD54 (ICAM-1) dependent manner. Moreover, indirect 
evidence indicates that EVs could also promote fibrolysis via the microRNAs they 
countain (117). 
Angiogenesis is proposed to promote fibrogenesis in the liver (118). Angiogenesis is 
increased by EVs generated in vitro from platelets, lymphocyte, and endothelial 
progenitors cells. Published results of Feldstein and colleagues (119) suggest that 
hepatocyte derived EVs contribute to angiogenesis and liver fibrosis in steatohepatitis, 
in a manner depandent on Vanin-1. In sight of this, the hypothesis is that the 
proangiogenic effect of EVs may have a role in promotion of fibrogenesis in the liver.  
31 
 
Portal hypertension is a frequent and severe complication of cirrhosis. It is a 
combination of structural and dynamic components. The structural components 
include fibrosis, regenerative nodule formation and vascular remodelling. EVs role in 
fibrosis is discussed above, but they might also contribute to vascular remodelling in 
cirrhosis through the release of EVs expressing Hedgehog ligands from hepatic stellate 
cells. These ligands induce the expression of inducible nitric oxide syntase (iNOS) (120).  
Moreover, portal myofibroblast release EVs that stimulate angiogenesis in a VEGF-
dependent manner, enhancing vascular remodeling (121). 
In cirrhotic patients, progressive splanchnic arterial vasodilatation may aggravates 
portal hypertension. EVs seem to contribute to vascular hypocontractility in patients 
with advance cirrhosis. This was demonstrated from Rautou et al. (122), which showed 
that patients with Child-Pugh B or C cirrhosis have increased circulating levels of EVs of 
Leukoendothelial, lymphocyte, erythrocyte and hepatocyte origin. These EVs decrease 
arterial blood pressure in mice through the transfer of phospholipids from EVs to 
endothelial cells. Interestingly, this was not observed with EVs from patients with 
Child-Pugh A cirrhosis. 
Role of EVs in hepatocellular carcinoma  
A study, published from Brodsky at al. (114), in a small group of HCC patients reported 
association between tumor size and plasma levels of hepatic and endothelial EVS. 
Furthermore, number of EVs decrease after HCC removal by liver transplantation. 
Many other group reported investigation of the role of EVs in the development of 
cancer. First of all, EVs promote angiogenesis. EVs containing the oncogenic epidermal 
growth factor receptor (EGFR) that could be taken by endothelial cells. Second, EVs 
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containing active oncogene (64). Third, EVs might also favour multidrug resistance, a 
major cause of unsuccessful cancer treatment (123). In the end, EVs may facilitates 
tumor invasion and metastasis, stimulating expression of matrix metalloproteinase in 
fibroblast by CD147 transport from T cell (124). 
Circulating procoagulant EVs in patients with acute liver failure  
Patients with acute liver failure seem to be prone to thrombosis than to bleeding 
complication, and intrahepatic thrombosis might exacerbate initial liver injury (125). 
The procoagulant activity of EVs, due to presence of phosphatidylserine and tissue 
factor at their surface, in patients with acute liver injury is fourfold and 38-fold higher 
respectively than that in healthy controls (126, 127). 
EVs as diagnostic and prognostic biomarkers in patients with liver disease 
A great interest has recently been directed toward using EVs as biomarker for disease 
diagnosis and prognosis. EVs isolated from several biological fluids (urine, bile, serum) 
can be characterized with proteomic, genomic and lipidomic approaches. 
Levels of EVs originating from CD4+ and CD8+ T cells are increased in patients with 
chronic hepatitis C, whereas levels of EVs from CD14+ and invariant natural killer T 
cells are augmented in patients with Non-alcoholic Fatty Liver Disease (NAFLD). This 
observation may be helpful in identifying the cause of liver blood test abnormalities in 
patients with HCV infection and the metabolic syndrome after liver transplantation 
(128). 
In liver rejection, EVs may be helpful in discriminating case of acute rejection, because 
EVs levels progressively decrease after surgery in patients without rejection (114). 
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Circulating EVs are potential noninvasive markers of disease severity and activity in 
chronic hepatitis C, NAFLD and cirrhosis (103).   
EVs levels were associated with the presence of the systemic inflammatory response 
syndrome. Multivariate logistic regression analysis showed that EVs concentration 
were indipendently associated with death and liver transplantation in patients with 
acute liver failure (127). Most of these circulating g EVs are CD41+. Thus, these 
originate from platelets, supporting the hypothesis that the severity of acute liver 
failure is related to systemic inflammatory response syndrome and coagulopathy.   
EVs and the complication of cirrhosis 
Probably, EVs don't have a role in the complications of cirrhosis, except for initial 
phase of development of portal hypertension. However, several properties of EVs 
contribute to ascites, hepatic encephalopathy, hepatopulmonary syndrome, 
portopulmonary hypertension and hepatorenal syndrome. 
The EVs ability to increase endothelial permeability and consequently, to contributed 
to the formation of ascites is still debated. Furthermore, EVs were found in the ascites 
of patients with ovarian and colorectal cancer but not in ascites of patients with 
cirrhosis (129). 
Instead, EVs contribute to hepatic encephalopaphy for several reasons: patients with 
cirrhosis and encephalopathy have 3.5-fold more leukoendothelial EVs than those 
without encephalopathy (122); EVs might increase blood-brain barrier endothelial cell 
permeability (130); brain endothelial cells might release EVs that induce astrocyte 
swelling (131).  
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The role of EVs in hepatopulmonary syndrome has not yet been assessed, but 
potentially EVs can modulate the main mechanism (pulmonary vasodilation and 
angiogenesis) involved in the development of this syndrome. 
Hepatorenal syndrome is characterized by functional renal failure in patients with 
cirrhosis and ascites. EVs may contributed to systemic and splancnic vasodilation (122). 
Moreover, EVs have been shown to induce renal vasoconstriction in sickle cell disease 
(132). 
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AIMS of THE STUDY 
The aim of this study was to characterize the molecular pathways involved in acute 
decompensation of cirrhosis and acute-on-chronic liver failure. This aim was pursued 
through the following intermediate goals: 
- Characterization of the inflammatory profile of patients by detection of pro-
inflammatory cytokines in plasma; 
- Evaluation of cytotoxic effects of plasma from patients with compensated cirrhosis, 
acute decompensation and acute-on-chronic liver failure on renal tubular cells 
considering the role of organ crosstalk on pathophysiology of liver disease; 
- Evaluation of expression of Inflammasome in renal tubular cells stimulated with 
plasma from patients with compensated cirrhosis, acute decompensation in cirrhosis 
and acute-on-chronic liver failure and in (PBMC) isolated from the same groups of 
patients; 
- Characterization of EVs from plasma of patients with compensated cirrhosis, acute 
decompensation and acute-on-chronic liver failure and healthy subjects like a vehicle 
of communication between organs; 
- Study of in vitro effects of EVs, extracted from plasma of patients with compensated 
cirrhosis, acute decompensation, acute-on-chronic liver failure and healthy subjects, in 
cells of renal tubular epithelium in order to investigate their role on pathogenesis of 
ACLF.   
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Material and Methods  
Patients  
Inclusion and Exclusion Criteria 
Outpatients with compensated cirrhosis: Inclusion criteria were as follows: (1) cirrhosis 
as diagnosed by liver biopsy or clinical, biochemical, ultrasound, and/or endoscopic 
findings; (2) age >18 years. Exclusion criteria were the follows: (1) hepatocellular 
carcinoma beyond Milan criteria; (2) ascites; (3) positive urine culture; (4) therapy with 
albumin; (5) autoimmune diseases; (6) genetic emocromatosis; (7) varices; (9) previous 
stories of decompensation.  
Patients with acute decompensation in cirrhosis: Inclusion criteria were as follows: (1) 
cirrhosis as diagnosed by liver biopsy or clinical, biochemical, ultrasound, and/or 
endoscopic findings; (2) age >18 years; (3) one or more major complications of liver 
disease (ie, ascites, encephalopathy, gastrointestinal hemorrhage, bacterial infection). 
Exclusion criteria: (1) liver transplantation; (2) Hepatocellular carcinoma; (3) 
hospitalization for scheduled procedures. 
ACLF patients: Inclusion criteria: (1) cirrhosis as diagnosed by liver biopsy or clinical, 
biochemical, ultrasound, and/or endoscopic findings; (2) age >18 years; (3) ACLF 
diagnosed according to the the EASL-CLIF consortium definition (Moreau et al 
Gastroenterology 2013). 
Study design and samples collection 
Demographic, clinical and routine laboratory data were collected at the inclusion in the 
study. Peripheral venous blood samples were collected from patients with Acute 
Decompensation and Acute-on-Chronic Liver Failure at diagnosis; patients with 
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compensated cirrhosis were enrolled at outpatients visit. Blood samples were 
collected in EDTA tubes and subsequently centrifuged for 10 min at 3,500 rpm. 
Following centrifugation, plasma was immediately separated from blood cells and 
stored at −80°C until use. All samples were processed within 4 h after collection. 
Collection and processing of control samples from healthy volunteers followed an 
identical protocol. 
Determination of IL-6, IL-1β and IL-18 in plasma 
Plasma was assayed for IL-6, IL-1β and IL-18. Cytokines concentration was measured by 
human instant enzyme-linked immuno-sorbent assay (ELISA) kit (eBioscience, San 
Diego, Calif., USA) with a fluorometric assay. Plasma was processed according to the 
manufacturer's instructions. Cytokines levels were measured in plasma at 450 nm by 
VICTOR X4 multilabel plate reader (Perkin Elmer Life Sciences, Waltham, Mass., USA) 
and concentrations (pg/ml) were calculated from the standard curve according to the 
manufacturer's protocol. Standard samples ranged from 7.8 to 500 pg/ml for IL-1β, 
from 3.1 to 200 pg/ml for IL-6  and from 78 to 5000 pg/ml for IL-18. Human IL-1β 
instant ELISA kit sensitivity is 0.7 pg/ml, human IL-6 instant ELISA kit sensitivity is 0.92 
pg/ml, and human IL-18 instant ELISA kit sensitivity is 9.2 pg/ml.  
Isolation of PBMCs from blood 
Human PBMC were isolated from 10 mL of venous blood using Ficoll–Hystopaque 
density centrifugation. After the centrifugation at 2200 rpm for 20 minutes at room 
temperature without brake, PBMC were collected from the interphase layer and 
washed with physiological solution (0,9% p/V NaCl)(Monico SPA, Mestre Venezia). 
PBMC were suspended in RPMI 1640 supplemented with 40% (v/v) FBS and storage at 
-80°C until further processing.  
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RTC Culture 
Primary cultures of human proximal Renal Tubular Cells (RTCs) were obtained from 
kidneys removed by surgical procedures from patients affected by renal carcinomas. 
An immortalized human proximal RTC line was generated by infection with a hybrid 
Adeno5/SV40 virus. The purity of the primary cultures was assessed on the basis of cell 
characterization, according to published criteria (133). RTCs were cultured in 
completed liquid-phase medium (RPMI-1640, PBI International, Milan, Italy) 
supplemented with 10% heat-inactivated fetal bovine serum for 30 min at 56°C, 2 mM 
L-glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin (Sigma Chemical Co., 
St. Louis, Mo., USA). These cells were maintained in a controlled atmosphere (5% CO2) 
at 37°C and passaged at 80% confluence checked by an inverted microscope. 
Induction of Apoptosis 
RTCs were treated with participants' plasma from the Compensated Cirrhosis, Acute 
Decompensation and healthy subject groups. The ability of plasma to induce apoptosis 
was evaluated at 24 h. Untreated cells were maintained in the same manner and used 
as an internal control. 
RTCs were plated at 2 × 106 cells per well in 6-well plates and incubated with 90% 
RPMI-1640 medium (with 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml 
streptomycin) and 10% of EDTA plasma from the Compensated Cirrhosis, Acute 
Decompensation and healthy subject groups in the standard condition (at 37°C in 5% 
CO2 for 24 h). Prior to use, RTCs were washed twice in Dulbecco's phosphate-buffered 
saline (PBS; without calcium and magnesium), pH 7.4. Each incubation was performed 
in triplicate. 
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Detection of cell viability by flow cytometry 
The Annexin V-FITC kit (Beckman Coulter, Brea, Calif., USA) is an apoptotic detection 
kit based on the binding properties of annexin V to phosphatidylserine and on the 
DNA-intercalating capabilities of propidium iodide (PI). Cells were washed twice with 
cold Dulbecco's PBS and resuspended in 500 μl of PBS at a concentration of 1 × 
106 cells/ml. 100 μl of this solution was incubated by 5 μl of FITC-conjugated annexin V 
and 2.5 μl PI (Beckman Coulter). The cells were gently vortexed and incubated for 15 
min at room temperature (25°C) in the dark. Then, 400 μl of 1× binding buffer was 
added to each tube. Analysis was performed by Navios Flow Cytometer (Beckman 
Coulter) to identify the subpopulations of the apoptotic cells within 1 h. Apoptotic cells 
were gated and enumerated by identifying those cells that exhibited FITC and PI 
staining. Annexin V-FITC labeling was used to quantitatively determine the percentage 
of cells that were undergoing apoptosis. PI was used to distinguish necrotic from non 
necrotic cells. The biparametric analysis showed three distinct populations: viable cells 
which had low FITC and low PI signals, apoptotic cells which had high FITC and low PI 
signals, and necrotic cells which had high FITC and high PI signals. A minimum of 
20,000 events were collected on each sample. 
Seeding Cells into xCELLigence Plates 
The E16 xCELLigence plates were prepared by addition of complete media (50 µL) to 
every well. After equilibration to 37 °C, plates were inserted into the xCELLigence 
station, and the base-line impedance was measured to ensure that all wells and 
connections were working within acceptable limits. The software automatically 
informs the researcher if any connection problems arise. Following harvesting and 
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counting, cells were diluted to the correct seeding density and added to the wells in 50 
µL.  
RNA extraction and quantification 
Total RNA was extracted using RNasy Trizol (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions and quantified by spectrophotometry at 260 nm. Total 
RNA (up to 1 mg) was reverse transcribed using kit iScript cDNA Synthesis (BioRad). 
The single cycle reaction consisted of 5 minutes at 25°C, 30 minutes at 42°C for to 
activated reverse transcriptase and 5 minutes at 5°C for to inactivate enzyme. 
Gene expression analysis 
After complementary DNA synthesis, quantitative real-time PCR reactions (RT-PCR) 
were carried out using the CFX96 Real-Time instrument (Bio-Rad Laboratories Inc, 
Hercules, CA, USA) and kit iQ SYBR Green Supermix (BioRad). The single-tube RT-PCR 
assays consisted of 1 denaturation cycle at 95°C for 30 s, 45 cycles of amplification at 
95°C for 10 s and 60°C for 30 s. Melt curve analysis was performed by ramping 
products from 65 to 95°C, acquiring fluorescence readings for each degree change. For 
genes, the fluorescence of the SYBR green dye was determined as a function of the 
PCR cycle number, giving the threshold cycle (CT) number. The CT values were used to 
quantify the PCR product, DCT was calculated by subtracting CT (control gene: Actin) 
from CT (target genes). The DCT value of the control was used arbitrarily as a constant 
that was subtracted from all other DCT values to determine DDCT value. In treated RTC 
cells and PBMC samples the relative expression were generated for each sample by 
calculating 2-ΔΔCt (134). 
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The following sets of primers were used: NFkB-F: 5′- GCCAACAGATGGCCCATACC -3′; 
NFkB-R: 5′- TGCTGGTCCCACATAGTTGC -3′; Caspase 1-F: 5'- ACATCCCACAATGGGCTCTG-
3'; Caspase 1-R: 5'- TCCACATCACAGGAACAGGC-3'; Caspase 3-F: 5'- 
TGCATACTCCACAGCACCTG-3'; Caspase 3-R: 5'-TTCTGTTGCCACCTTTCGGT-3'; TNF-α-F: 
5'-CCAGACCAAGGTCAACCTCC-3'; TNF-α-R: 5'-CCCTCCCAGATAGATGGGCT-3'; IL-1β-F: 
5'-CCACCTCCAGGGACAGGATA-3'; IL-1β-R: 5'-CAACACGCAGGACAGGTACAG-3'; NLRP3-
F: 5'-GAGGAAAAGGAAGGCCGACA-3'; NLRP3-R: 5'-CCCGGCAAAAACTGGAAGTG-3'; 
PYCARD-F: 5'-CCTCAGTCGGCAGCCAAG-3'; PYCARD-R: 5'-GGTACTGCTCATCCGTCA-3'; 
TLR2-F: 5'-CCCTGGGCAGTCTTGAACAT-3'; TLR2-R: 5'-GGCTTGAACCAGGAAGACGA-3'; 
TLR4-F: 5'-TCCCCTGAGGCATTTAGGCA-3'; TLR4-R: 5'-GAAAAGGCTCCCAGGGCTAA-3'. 
The housekeeping gene Actin was amplified in parallel in all amplification sets.  
EVs isolation and count 
Plasma EVs from cirrhotic patients and healthy subject were collected from 1 ml of 
plasma. EVs were isolated from plasma using a two-step differential centrifugation 
protocol based on a first low-speed centrifugation, 2000 g for 5 minutes, in order to 
remove cells, cellular debris and apoptotic bodies. The supernatant was subsequently 
ultracentrifuged at 100,000 g for 1 h at 4°C washed in serum-free medium 199 (M-199) 
to sediment plasma vesicles. Pellet of EVs was resuspended in M-199 (Sigma Aldrich) 
and 1% DMSO (Sigma-Aldrich) was added to allow freezing storage in -80°C until use. 
To trace EVs by fluorescent microscopy or FACS analysis, EVs were labelled with the 
red fluorescent aliphatic chromofore intercalating into lipid bilayer PKH26 DYE (Sigma-
Aldrich). After labelling, EVs were washed and ultrecentrifuged at 100,000 g for 1 
hours at 4°C. EVs pellets were suspended in M-199and stored at -80°C until use. 
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Plasma EVs were analysed by nanoparticle tracking analysis (NTA), using the NanoSight 
LM10 System (NanoSight Ltd, Amesbury, UK), configured with a 405 nm laser and a 
high sensitivity digital camera system as previous described (135). Briefly, EVs coming 
from 1 ml of plasma were resuspended in 200 μl of M-199 and 1% DMSO. Each 
samples was then diluted 1:1000 in physiologic solution (Fresenius Kabi, Runcorn, UK). 
For this analysis, a monochromatic laser beam at 405 nm was applied to the diluted 
suspension of EVs. For each sample, three videos of 30 seconds duration were 
recorded and number of particles/ml and mean size was averaged. NTA post-
acquisition settings optimized and kept constant between samples, and each video 
was then analysed to give the mean, mode, and median visicles size together with an 
estimation of the concentration.   
EVs characterization by FACS 
Flow cytometry analysis was performed with a FACSCalibur machine using CellQuest 
software (Becton Dickinson Bioscience Pharmingen, Franklyn Lake, NJ, USA). As EVs are 
too small for FACScan analysis, we bound EVs to surfactant-free white 
aldehyde/sulfate latex beads 4% w/v, 4 mm diameter (Molecular Probes, Invitrogen) 
(136). We incubated beads with EVs for 30 minutes at RT and then overnight at 4°C in 
a final volume of 1 ml PBS-BSA 0.5%. Then the adsorbed EVs were divided in different 
vials and incubated with antibodies diluted 1:50, for 15 minutes at 4°C. The adsorbed 
EVs were then washed and analyzed with a FACSCalibur and CellQuest software. Flow 
cytometry was performed using anti-human monoclonal antibodies (MAbs): FITC 
conjugated CD41(Becton Dickinson, San Jose, CA), CD42b and CD14 (Dako, 
Copenhagen, Denmark) and PE-conjugated CD62E, CD31, α4 integrin(Becton 
Dickinson, San Jose, CA), L-selectin (Dako, Copenhagen, Denmark), β1-integrin 
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(Chemicon Int., Temecula, CA). Comparison of plasma EVs among groups was 
performed by evaluating the relative amount of EVs positive for a selected marker in 
respect to all EVs, in conditions where the same quantity of EVs was tested 
(concentration detected by NTA analysis).  
Viability and Proliferation Assays on RTCs 
RTCs were cultured on 24-well plates (Falcon Labware, Oxnard, CA) at a concentration 
of 5 × 104 cells/well and incubated with 5∙108 EVs/ml for 24h and 250 μg/ml XTT 
(Sigma,St. Louis, MO) in a medium lacking phenol red. The absorption values at 450 nm 
(XTT) were measured in an automated spectrophotometer at different time points. All 
experiments were performed in triplicate. 
Detection of Apoptosis - TUNEL Assay in vitro on RTCs 
RTCs were subjected to TUNEL assay (terminal deoxynucleotidyltransferase (TdT)-
mediated dUTP nick end labelling) (ApopTag, Oncor, Gaithersburg, MD) after starving 
for 12 hrs without FCS and subsequent incubation with stimulation with EVs for 24h. 
Then, cells were fixed in 1% paraformaldehyde, post-fixed in pre-cooled ethanol and 
acetic acid 2:1, incubated with TdT enzyme in a humidified chamber at 37° C for 1 hr 
and counterstained with antidigoxigenin-FITC antibody and with propidium iodide (1 
μg/mL). Samples were analyzed under a fluorescence microscope and green-stained. 
Apoptotic cells were counted in 10 non-consecutive microscopic fields. 
ROS detection 
Image-iT LIVE Green Reactive Oxygen Species (ROS) Detection Kit was used to analyze 
oxidative stress on RTCs as suggested by manufacturer (Life Technologies). Briefly, 5-
(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) was 
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added to RTCs in different experimental conditions: after 30 min, cells were fixed with 
4% paraformaldehyde and then counterstained with Hoechst and analyzed by FACS 
analysis. 
Detection of FITC-conjugated albumin uptake 
Albumin uptake was studied after incubation of RTCs previously exposed to EVs with 
50 μg/ml of FITC-conjugated human albumin (Sigma, St. Louis, MO, USA) at 37°C for 
two hours. After FITC-albumin challenge, RTCs were extensively washed twice with 
PBS, detached from tissue culture plates with EDTA and analysed by FACS. 
FACS analysis 
For FACS analysis, after exposure to EVs, RTCs were detached from tissue culture 
plates with EDTA, washed twice with one times PBS and fixed with 4% 
paraformaldehyde. Cells were then stained for one hour at 4°C with antibodies 
directed to human zonula occludens-1 (ZO-1), megalin, PGC-1alpha (Santa Cruz 
Biotech, Santa Cruz, CA, USA). After incubation with primary antibodies, samples were 
washed twice with PBS and incubated with appropriated FITC-conjugated secondary 
antibodies (Sigma Aldrich, MO, USA) for 30 minutes at room temperature. At the end 
of staining, cells were newly washed and subjected to FACS analysis (Becton Dickinson, 
Franklin Lakes, NJ, USA). All incubation periods were performed using PBS containing 
0.25% BSA, 0.1% saponine and 0.0016% sodium azide. 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism (Prism 5 for Windows, Version 
5.01). Continuous variables are presented as median (25%–75% percentile), according 
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to their distribution. The difference between 3 or more groups of these variables was 
analyzed with One-way ANOVA and Kruskal-Wallis test. The difference between two 
groups was analyzed with t-test. Significance level for all tests was set at p<0.05.  
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Results 
Patients 
In the first part of the study, 22 patients were enrolled: 12 patients with compensated 
cirrhosis, 8 with acute decompensation of cirrhosis and 2 with acute-on-chronic liver 
failure. In Table 2 demographic and biochemical data about the three different groups 
have been reported. 
Table 2: Demographic and biochemical data of patients included. Data are expressed as median and 
range. Differences between groups were analyzed using ANOVA test. 
  
    
 
range 
Compensated 
Cirrhosis 
Acute 
Decompensation 
Acute-on-chronic p-value 
male (%)  77% 75% 50% 
 
age (y)  63 (53-73) 61 (51-64) 59 (55-64) ns 
Total bilirubin (μmol/L) 1.7-17.0 14.3 (9.3-20.0) 80.3 (32.4-124.0) 590.8 (501.6-679.9) <0.0001 
Direct bilirubin  (μmol/L) 0.0-3.4 6.8 (4.4-8.8) 58.9 (21.8-86.6) 477.0 (407.2-546.7) <0.0001 
INR 0.88-1.13 1.1 (1.0-1.1) 1.4 (1.3-1.7) 1.9 (1.8-1.9) 0.001 
Creatinine  (μmol/L) 62-115 72.0 (65.0-92.0) 67.0 (60.0-84.5) 204.0 (150.0-258.0) ns 
Urea (mmol/L) 2.50-7.50 5.6 (4.3-7.2) 6.7 (4.8-9.6) 27.5 (19.7-35.2) ns 
Na (mmol/L) 136-145 140 (139-140) 133 (130-135) 132 (129-126) 0.001 
K (mmol/L) 3.4-4.5 4.1 (4.0-4.2) 3.8 (3.7-4.4) 4 (3.9-4.2) ns 
White blood cells (*10.9/L) 4.40-11.00 5.3 (4.5-7.7) 6.6 (4.7-9.1) 15.6 (11.6-19.6) ns 
Red blood cells (*10.12/L) 4.50-5.90 4.9 (4.3-5.0) 3.0 (2.8-3.3) 3.4 (3.2-3.7) <0.0001 
Haemoglobin (g/dL) 14-17.5 13.8 (12.5-14.4) 9.7 (9.3-10.3) 12.0 (10.3-13.6) 0.002 
Platelets (*10.9/L) 150-450 148.5 (70.8-201.2) 78.0 (55.5-126.0) 59 (59-59) ns 
AST (U/L) 10-45 31 (25-50) 51 (41-64) 43 (43-43) ns 
ALT (U/L) 10-50 30 (22-44) 32 (24-37) 31 (31-31) ns 
GGT (U/L) 3-65 32 (21-45) 37 (30-46) 99 (99-99) ns 
ALP (U/L) 56-128 75 (63-99) 124 (103-166) 250 (250-250) 0.006 
Albumin (g/L) 1-47 43 (41-44) 29 (25-31) 30 (30-30) 0.003 
 
 
    
 
 
    
 
 
    
Inflammatory profile in patients 
Plasma inflammatory cytokines levels were measured by ELISA assay in all patients. IL-
6, IL-1β and IL-18 levels did not show significantly differences between the groups 
(Table 3). Unfortunately, the number of patients whit acute decompensation of 
cirrhosis and acute-on-chronic groups was really low.  
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Table 3: IL-6, IL-1β and IL-18 levels in plasma of patients detected with ELISA assay. Data are expressed 
as median and range. Differences between groups were analyzed using ANOVA test. 
   
Compensated 
cirrhosis 
Acute decompensation Acute-on-chronic p-value 
IL-6   (pg/ml)  32.5 (27.4-47.1) 41.1 (31.3-58.5) 42.24 0.631 
IL-1β (pg/ml)  9.6 (9.4-10.1) 10.3 (8.8-11.1) 10.11 0.827 
IL-18 (pg/ml)  187 (138.1-220.2) 292.4 (167.9-408.6) 263.6 0.318 
Statistical analysis: non-parametric Kruskal Wallis test for n-indipendent samples  
 
Effect of plasma on RTCs viability 
Cytotoxic effect of plasma from patients was assayed in RTCs by flow-cytometry 
according to (137). The RTCs incubated with 10% v/v of plasma from patients with 
compensated cirrhosis, acute decompensation of cirrhosis and acute-on-chronic liver 
failure did not show significantly different levels of viability, apoptosis and necrosis 
after 24 hrs of stimulation (Figure 4). 
Figure 4: cell viability, apoptosis and necrosis detected by FACS after 24 hours of stimulation with 
plasma from the three groups of patients enrolled. Data are represented as single values and median. 
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Gene expression analysis on treated RTCs  
After stimulation, RTCs were collected for gene expression analysis. Total RNA was 
extracted and expression of the main molecules of inflammasomes (NFkB, NLRP3, 
Caspase-1 and -3, TNF-α, PYCARD and IL-1β) was assayed. The expression levels of 
molecules of inflammasome was not significantly different between the groups (Table 
4). 
Table 4: gene expression in RTCs stimulated with plasma from patients of the three groups enrolled. 
Data are expressed as median and range. Differences between groups were analyzed using ANOVA test. 
   Compensated cirrhosis Acute decompensation Acute-on-chronic p-value 
NFkB  1120 (1040-1528) 960 (728-1079) 924 (833-1016) 0.354 
NLRP3  1.7 (1.5-1.8) 1.0 (0.9-1.2) 1.2 (1.2-1.2) 0.159 
Caspase-1  27.7 (20.0-28.5) 9.1 (4.9-13.2) 2.1 (1.6-2.6) 0.056 
TNF- α  0.3 (0.3-0.3) 0.1 (0.1-0.3) 0.4 (0.3-0.5) 0.493 
PYCARD  2.7 (2.3-2.8) 2.7 (2.1-3.6) 1.4 (1.4-1.5) 0.096 
IL-1β  3.3 (2.6-3.8) 1.5 (1.1-3.6) 0.3 (0.2-0.3) 0.073 
Caspase-3 2.3 (2.2-2.3) 1.0 (0.9-1.9) 0.7 (0.6-0.8) 0.254 
The data are reported  as 2-∆∆CT 
Statistical analysis: non-parametric Kruskal Wallis test for n-indipendent samples  
 
Gene expression analysis on PBMC from patients 
Gene expression analysis of molecules of inflammasomes and the two main receptors 
of PAMPS and DAMPS (TLR2 and 4) was assayed also in PBMC extracted from whole 
blood of patients.  No differences in gene expression of molecules of inflammasome 
were found, except for TLR-2 (Table 5). Its expression in PBMC  from patients with 
acute decompensation was higher than compensated cirrhosis (p=0.031).  
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Table 5: gene expression in PBMC from patients of the three groups enrolled. Data are expressed as 
median and range. Differences between groups were analyzed using ANOVA test. 
 
   Compensated cirrhosis Acute decompensation Acute-on-chronic p-value 
NFkB  
0.0014 
(0.0011-0.0025) 
0.0007 
(0.0003-0.0012) 
0.0011 
(0.0010-0.0012) 
0.391 
NLRP3  
0.0008 
(0.0005-0.0011) 
0.0004 
(0.0003-0.0005) 
0.0006 
(0.0005-0.0007) 
0.441 
Caspase-1  
0.16 
(0.15-0.35) 
0.10 
(0.06-0.15) 
0.08 
(0.06-0.09) 
0.208 
TNF- α  
0.0019 
(0.0016-0.0091) 
0.0006 
(0.0003-0.0011) 
0.0005 
(0.0005-0.0006) 
0.077 
PYCARD  
0.075 
(0.062-0.120) 
0.065 
(0.036-0.078) 
0.043 
(0.034-0.051) 
0.441 
IL-1β  
0.0026 
(0.0021-0.0034) 
0.0015 
(0.0007-0.0022) 
0.0013 
(0.0010-0.0016) 
0.441 
Caspase-3  
0.0026 
(0.0021-0.0037) 
0.0012 
(0.0011-0.0027) 
0.0022 
(0.0020-0.0023) 
0.510 
TLR-2 
0.0043 
(0.00021-0.015) 
0.016 
(0.011-0.030) 
0.0071 
(0.0070-0.014) 
0.036* 
TLR-4 
0.000025 
(0.0000061-0.0018) 
0.0013 
(0.000081-0.0021) 
0.00080 
(0.00061-0.0012) 
0.422 
The data are reported  as 2-∆∆CT 
Statistical analysis: non-parametric Kruskal Wallis test for n-indipendent samples  
 
Evaluation of cell viability by xCELLigence Real-Time Cell Analyzer 
In a second phase of the study we included healthy subjects as control groups and we 
incremented the number of patients with acute-on-chronic liver failure (n=5).  
Cytotoxicity assay was performed with the xCELLigence Real-Time Cell Analyzer (RTCA) 
in order to measure RTCs viability and proliferation in real time after stimulation with 
plasma of patients and controls. It was assayed only a small group of patients for 
setting-up. In Figure 5 data about percentage of cell viability after 24 hrs of stimulation 
with 10% v/v of plasma has been reported. After these first experiments it was clear 
that there was not a defined trend in viability rate in the different groups.  
The same experiment was performed adding albumin to cell medium with 10% v/v of 
plasma from patient. It was used solution containing 0-20-45 g/L of albumin. Figure 6 
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shows that physiologic concentration of albumin (45 g/L) reduced cell death respect 
the absence of albumin in medium. 
Figure 5: viability rate in cells stimulated for 24 hours with plasma from patients and healthy subject 
enrolled. Data are represented as single values and median.  
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Figure 6: viability, represented as normalized cell index, in cell treated with plasma from one patients in 
medium containing different concentration of albumin. Data are expressed as single values and median. 
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Characterization of extracellular vesicles in cirrhotic patients  
Patients 
EVs analysis was carried on 48 patients: 12 healthy subjects, 12 patients with 
compensated cirrhosis, 13 patients with acute decompensation in cirrhosis and  11 
patient with acute-on-chronic liver failure. Table 5 record demographic and 
biochemical data of all patients. As expected there was a stepwise increase in bilirubin, 
INR, serum creatinine, white blood cells and haemoglobin moving from compensated 
cirrhosis to acute decompensation and acute-on-chronic liver failure. 
Table 5: Demographic and biochemical data of patients included. Data are expressed as median and 
range. Differences between groups were analyzed using ANOVA test. 
 Compensated 
Cirrhosis 
Acute 
Decompensation 
Acute-on-chronic p-value 
male (%) 75% 53.8% 81.8%  
age (y) 61.5 (52.5-70.5) 51.0 (43.8-65.3) 54.0 (51.0-66.0) ns 
Total bilirubin (μmol/L) 26.0 (14.2-35.3) 54.6 (33.5-138.2) 300.2 (151.1-434.4) <0.0001 
Direct bilirubin  (μmol/L) 10.5 (6.3-13.0) 38.8 (22.1-103.3) 244.5 (117.0-356.3) <0.0001 
INR 1.3 (1.0-1.3) 1.5 (1.4-1.6) 1.8 (1.7-2.8) <0.0001 
Creatinine  (μmol/L) 69.5 (59.8-86.0) 68.0 (52.5-79.0) 117.0 (73.0-312.0) 0.017 
Urea (mmol/L) 4.3 (3.7-7.5) 3.8 (2.9-8.7) 11.6 (8.7-26.5) 0.0024 
Na (mmol/L) 140 (137-141) 135 (127-137) 133 (130-137) 0.0198 
K (mmol/L) 4.3 (4.0-4.4) 3.7 (3.3-4.2) 4.3 (3.7-4.7) ns 
White blood cells (*10.9/L) 3.7 (2.8-4.3) 5.8 (4.1-6.6) 10.0 (6.8-11.8) 0.0008 
Red blood cells (*10.12/L) 4.6 (4.3-4.9) 2.8 (2.7-3.6) 3.0 (2.5-3.5) <0.0001 
Haemoglobin (g/L) 125 (102-149) 101 (87-105) 95.0 (83-116) 0.0298 
Platelets (*10.9/L) 53.0 (38.0-120.3) 95.0 (78.0-134.0) 59.0 (43.0-65.0) 0.0242 
AST (U/L) 41.0 (29.3-89.0) 67.0 (41.8-82.8) 118.0 (50.0-215.0) ns 
ALT (U/L) 30.0 (18.8-100.3) 34.0 (17.0-44.0) 58.0 (31.0-128.0) ns 
GGT (U/L) 37.5 (18.8-103.3) 66.0 (44.5-378.0) 48.5 (14.0-95.3) ns 
ALP (U/L) 86.5 (54.3-104.8) 156.0 (118.0-165.0) 138.0 (98.5-221.0) 0.0057 
Albumin (g/L) 40.0 (38.0-46.0) 28.0 (24.0-36.0) 29.0 (26.0-32.0) 0.0005 
 
    
 
Detection of plasma EVs in cirrhotic patients and healthy subjects 
EVs in plasma obtained from all enrolled patients and healthy subjects were quantified 
and size was determined by NanoSight analysis. Data collected about size and 
concentration were reported in Table 7.  
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Plasma EVs showed a heterogenic size between the groups: the size of EVs from 
healthy subjects was significantly lower only respect Acute-on-chronic group 
(p=0.0019).    
Table 7: size and concentration of EVs analyzed in the four groups. Data are reported as median of 
mode values calculated by Nanosight, and range. 
samples Mode size (nm) Concentration 
(particles/ml) (*10
11
) 
healthy subject 167,5 (130,6-192,1) 0,2 (0,2-0,3) 
compensated cirrhosis 191,0 (163,2-238,9) 0,4 (0,3-0,5) 
Acute Decompensation 189,9 (174,4-223,0) 0,3 (0,2-0,7) 
Acute-on-chronic 220,6 (193,3-250,9) 0,7 (0,5-1,5) 
 
Data about concentration of EVs showed a trend toward their increase in patients with 
cirrhosis and ACLF, as shown in Figure 7. In fact the concentration of EVs from Acute-
on-chronic group was significantly higher than concentration in healthy subjects 
(p=0.0021). 
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Figure 7: histogram of concentrations (in particles for milliliter) of EVs extracted from plasma of patients 
enrolled. Data are represented as mean ± standard error of the mean (SEM). Statistical analysis was 
made with ANOVA test. 
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We then stratified any group of patients according to the most frequent size of EVs as 
follows: "less than 150 nm", "between 150 and 200 nm" and "up to 200 nm". As shown 
in Figure 8, the percentage of patients having a prevalence of small vesicles was higher 
in healthy subjects and disappeared in patients with acute-on-chronic liver failure. 
Controversely,  the percentage of big vesicles was higher in acute-on-chronic liver 
failure group than the other groups. 
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Figure 8: in each group of subject enrolled, EVs is grouped by size. Healthy subject have EVs smaller than 
200 nm. Acute-on-chronic patients have EVs bigger than 150 nm. 
 
Characterization of EVs 
Cytofluorimetric analysis of the EVs using  the antibody showed in Table 8 was used for 
determining the origin of EVs. 
Table 8: selected markers for EVs origin characterization 
Marker  Localization  Function  
CD41  platelets membrane glycoprotein  
CD42b  platelets Von Willebrant factor Receptor  
CD14  Monocyte, macrophages, granulocytes membrane receptor  
CD31/PECAM-1  endothelium cell adhesion  
CD62E/E-selectin  platelets activated endothelium cell adhesion  
 
Analysis of EVs showed the absence of typical platelet markers such as CD41 and 
CD42b and also for monocyte/macrophages/granulocyte marker CD14 (Figure 9 A, B, 
C). The endothelial marker CD31 was expressed in EVs from patients with Acute 
Decompensation of cirrhosis and Acute-on-chronic liver failure (Figure 9 D). EVs from 
Acute-on-chronic patients were positive for CD42E, a platelet activated endothelium 
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marker, and this expression was significantly higher respect healthy subjects and 
patients with compensated cirrhosis (p=0.0041 and p=0.0111, respectively)(Figure 9 E). 
EVs were characterized also for the presence of molecules involved in vesicles 
internalization in target cells or tissue (integrins and selectins) and a molecule crucial 
for cell signaling in both adaptive and innate immunity, CD40 Ligand (Table 9). 
 
Table 9: Other selected markers for EVs characterization 
Marker  Localization  Function  
CD40 Ligand/CD154  T activated cells  cytokines production, macrophages activation  
CD29/β1-integrin  focal adhesion  cell adhesion  
α-4 integrin  leukocytes  cell adhesion  
CD62/L-selectin  white blood cells  hinder MV endocitosis  
 
α4 , β1-integrin and L-selectin expression was higher in EVs from acute-on-chronic liver 
failure patients than healthy subjects (all p=0.0017). L-selectin was more expressed in 
patients with acute-on-chronic liver failure than in those with compensated cirrhosis 
(p=0.0014)(Figure 9 F, G, H). Expression of CD40 Ligand was higher in all group of 
patients than healthy subject (healthy vs compensated p=0.0009; healthy vs acute 
decompensation p=0.0226; healthy vs acute-on-chronic p<0.0001) and between 
patients, the expression was higher in acute-on-chronic liver failure group than in 
compensated cirrhosis (p=0.0008)(Figure 10). 
 
 
 
 
Figure 9: Graphs represent EVs characterization. Comparison of EVs among groups was performed by 
evaluating the relative amount of EVs positive for a selected marker in respect to all EVs. Data are 
shown as single values, median and interquartile range. Statistical analysis was performed using the 
Mann-Whitney test. 
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Figure 10: CD40L expression in EVs for each group. Comparison of EVs among groups was performed by 
evaluating the relative amount of EVs positive for a selected marker in respect to all EVs. Statistical 
analysis was performed using the Mann-Whitney test. 
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When we divided patients in groups according to CD40 Ligand expression percentage, 
patients with higher level of CD40 Ligand expression (>50%) were almost completely  
acute-on-chronic, instead healthy subjects expressed lower levels of this molecule 
(<5%)(Figure 11). 
 
 
 
 
 
 
 
 
 
Figure 11: expression levels of CD40L in EVs is categorized in the histogram. Classes are: CD40L levels 
lower than 5% in EVs, levels between 5 and 25%, between 25 and 50% and expression levels above 50% 
in EVs. In ordinate axis is represented the number of patients. 
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EVs: In vitro experimentation 
Effect of EVs on RTC viability 
EVs cytotoxic effects in vitro was tested on RTCs (Figure 12). After 48 hr of incubation, 
cells showed decrease in cell viability at MTT assay when incubated with EVs from 
patients with acute decompensation and acute-on-chronic respect controls and EVs 
from patients with compensated cirrhosis (all p<0.0001). 
Figure 12: Effect of EVs on RTCs viability, expressed as optical density (O.D.). Less is O.D. lower is cell 
viability. Statistical analysis was performed using the Mann-Whitney test. 
   
 
 
 
 
 
 
 
 
Apoptosis was detected on RTCs stimulated with EVs by TUNEL assay (Figure 13). 
Apoptotic rate increased in cells incubated with EVs from patients than in those 
incubated with EVs from healthy subject (all p<0.0001). Apoptotic rate was 
significantly higher in acute-on-chronic liver failure group than in compensated 
cirrhosis group (p=0.0006). 
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Cell stimulation with EVs led to massive production of ROS when vesicles belonging to 
patients with acute decompensation or acute-on-chronic liver failure were used 
(p<0.0001). Instead, there was no significant ROS production from cells incubated with 
EVs from patients with compensated cirrhosis respect healthy subjects (Figure 14). 
Figure 13: apoptosis in RTCs stimulated with EVs assayed with TUNEL. In order axis there is the mean 
number of apoptotic cells detected for field. Data is represented as single value, median and 
interquartile range. Statistical analysis was performed using the Mann-Whitney test.   
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Figure 14: ROS production in RTCs incubated with EVs. Comparison of ROS among groups was 
performed by evaluating the relative amount of cells positive for a selected marker in respect to all cells. 
Data is represented as single value, median and interquartile range. Statistical analysis was performed 
using the Mann-Whitney test. 
 
 
 
 
 
 
 
 
 
Effect of EVs on cellular functions and activity 
Using Albumin-fitc it was possible to track transportation of albumin inside epithelial 
tubular cells. Figure 15 shown  a decrease in albumin transportation in cells incubated 
with EVs from patients with acute decompensation and acute-on-chronic liver failure 
(p<0.0001). One of albumin transporters, Megalin, was detected by flow cytometry 
assay and its expression didn't change between the groups (Figure 16).  
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Figure 15: albumin-fitc intake in RTCs incubated with EVs. Comparison of albumin amount in cells among 
groups was performed by evaluating the relative amount of cells positive for albumin in respect to all 
cells. Data is represented as single value, median and interquartile range. Statistical analysis was 
performed using the Mann-Whitney test.  
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Figure 16: Megalin expression in RTCs incubated with EVs. Comparison of Megalin expression in cells 
among groups was performed by evaluating the relative amount of cells positive for Megalin in respect 
to all cells. Data is represented as single value, median and interquartile range. Statistical analysis was 
performed using the Mann-Whitney test.  
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The expression of cell-cell junction protein ZO-1 decreased in cells incubated with EVs 
from patients than controls, but a significant difference was found only between 
patients with acute decompensation and healthy subjects (p=0.0166) (Figure 17). 
Figure 17: ZO-1 expression in RTCs incubated with EVs. Comparison of ZO-1 expression in cells among 
groups was performed by evaluating the relative amount of cells positive for ZO-1 in respect to all cells. 
Data is represented as single value, median and interquartile range. Statistical analysis was performed 
using the Mann-Whitney test.  
ZO-1
he
at
hy
 s
ub
je
ct
s
co
m
pe
ns
at
ed
 c
irr
ho
si
s
ac
ut
e 
de
co
m
pe
ns
at
io
n
A
cu
te
-o
n-
ch
ro
ni
c
0
20
40
60
80
*

(F
L
1
-H
):
 F
IT
C
 
It was determined also the expression of PGC1α, a molecule involved in mitochondria 
biogenesis, in renal tubular cells stimulated with EVs. As shown in Figure 18 there was 
no difference in PGC1α expression between the groups.  
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Figure 18: PGC1α expression in RTCs incubated with EVs. Comparison of PGC1α expression in cells 
among groups was performed by evaluating the relative amount of cells positive for PGC1α in respect to 
all cells. Data is represented as single value, median and interquartile range. Statistical analysis was 
performed using the Mann-Whitney test.  
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Discussion 
In this project it was studied the acute and acute-on-chronic liver failure from a 
biological point of view. Starting from the patients, it was carry on a study with 
different approaches, in order to in vitro characterize liver disease. The first approach 
was focused on the characterization of inflammatory profile of the patients through 
the detection of pro-inflammatory cytokines in plasma; the second hypothesized a 
cytotoxic activity of molecules released in the blood flow from the organ or organs 
injured. The last one was born on the need of focusing the attention on a single 
component of plasma, the extracellular vesicles. 
Patients enrolled in the first part of the study showed abnormalities in laboratory 
findings including elevated serum bilirubin, prolonged prothormbin time (elevated 
international normalized ratio, INR) and hyponatremia. The levels in these parameters 
significantly differed between the groups of cirrhotic patients, acute decompensation 
and patients with acute-on-chronic liver failure. Groups differed also for ALP levels and 
serum albumin concentration. Creatinine and urea, markers of kidney function, were 
elevated respect physiological range in patients with acute-on-chronic liver failure. 
Renal dysfunction is critical in the definition of acute-on-chronic liver failure and it has 
been found a powerful predictor of mortality in patients with cirrhosis. Indeed, these 
patients have a high risk to develop AKI. AKI is defined as an abrupt (within 48 hours) 
reduction in kidney function currently defined as an absolute increase in serum 
creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 μmol/l), or a percentage increase 
in serum creatinine of more than or equal to 50% from baseline which is known, or 
presumed, to have occurred whithin the prior 7 days (138, 139). AKI can be found in 
27–49% of patients hospitalized for an acute decompensation of cirrhosis (140-143). 
66 
 
AKI markedly increased mortality in cirrhotic patients, whose 3-month mortality rate 
reached 26% (144). Increasing evidences show that inflammatory response is involved 
in apoptosis and cellular dysfunction during AKI, mediated by the activation of 
inflammasome (145). Furthermore, also acute decompensation and acute-on-chronic 
liver failure were characterized by systemic inflammation (4) and activation of 
inflammasome (23). For these reasons, first step of the  study was to characterize the 
inflammatory profile of patients through the detection of plasma levels of IL-6, IL-1β 
and IL-18. The second one was to assess the cytokines release from cells in which 
inflammasome was activated. Unfortunatly, this determination was difficult to perform 
because of the small sample size, especially for acute-on-chronic liver failure group. 
However, these samples were part of a group of 522 patients with decompensated 
cirrhosis (237 with acute-on-chronic liver failure) and 40 healthy subjects in which it 
was measured a panel of 29 cytokines and marker of systemic oxidative stress by Clària 
J. and co-workers and recently published in Hepatology (20). It was shown that 
patients with acute decompensation and without acute-on-chronic liver failure had 
very high baseline levels of pro-inflammatory cytokines, such as TNF-α, IL-6, IL-8, 
macrophage chemotactic protein 1 (MCP-1), inducible protein 10 (IP10), macrophage 
inflammatory protein(MIP)-1β, granulocyte macrophage colony-stimulating factor 
(GM-CSF) and granulocyte colony-stimulating factor (G-CSF). Moreover, patients with 
acute-on-chronic liver failure showed higher levels of pro-inflammatory cytokines than 
those without. Surprisingly, Clària J. described also a characteristic cytokines profiles 
according to the type of precipitating event of acute-on-chronic liver failure. Finally, in 
the paper was highlighter the pivotal role of systemic inflammation as the primary 
driver of acute-on-chronic liver failure (20).  Few years ago, Baroja-Mazo and 
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colleagues (146) found that activation of inflammasomes led to the release of 
functional oligomeric inflammasome particles containing both NLRP3 and ASC that 
acted as danger signals to amplify inflammation by promoting the activation of 
caspase-1 extracellularly and in surrounding macrophages following internalization of 
the particles. In macrophages, caspase-1 induces the specific type of cell death called 
'pyroptosis'. It was clear that this effect hit not only macrophages but overexpression 
of ASC was found able to induce the death also in culture of monkey kidney cells (146). 
For this reason, one aim of this study was to determined the cytotoxic effect of plasma 
from patients enrolled on renal epithelial cell line. First of all, the effect of circulating 
molecules in activation of inflammasome in cells was evaluated by gene expression of 
inflammasome components (receptors, catalytic domain, adaptor molecule, etc..) in 
epithelial cell line. Secondly, the cell death as a consequence of inflammasome 
activation after stimulation of cell culture with plasma from patients was assessed. 
This was performed by detection of annexin V and propidium iodide bond in cells. This 
approach has been largely applied for understanding the mechanism of cell death 
involved in Cardiorenal Syndromes pathophysiology (137, 147-150). In this syndrome, 
apoptosis played a pivotal role in organ injury and failure. A dual apoptotic pathway 
activation in cells incubated with plasma from patients was found, as well as the 
production of pro-inflammatory cytokines in vitro (137, 148).   
Unfortunately, in patients enrolled in the first phase of the study no clear trend in cell 
viability or death was identified among groups. It has been hypothesized that both the 
low sample size and the complexity of plasmatic fluid may be responsible of these 
results. Patients with acute decompensation in cirrhosis, and acute-on-chronic above 
all, had a molecular ensemble in plasma that included cell grow factors, drugs, pro- 
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and anti-inflammatory cytokines and mediators, excess of bilirubin and low levels of 
the main molecules scavenger such as albumin, that might interact with cells and gave 
conflicting signals. Furthermore, therapy for patients admitted in hospital (both 
patients with acute decompensation and acute-on-chronic) might represent another 
confounding factor that influences in vitro cell viability.      
The in vitro effect of the main active drugs administered to patients with compensated 
and decompensated cirrhosis have been reported. Potassium canrenoate, a synthetic 
steroid and is used in the treatment of hypertension, induced a dose-dependent 
degree of DNA fragmentation and of DNA repair synthesis in primary cultures of 
hepatocytes from rat and human donors (151). Beta blockers are known to have 
favorable effects on endothelial function partly because of their capacity to reduce 
oxidative stress (152). Controversial results were collected for vitamin B12. A recent 
study showed that cytotoxicity activity in Caco-2 cells, a colon cancer cells, was lacked 
for vitamin B12 (153). It was also observed mitochondrial ROS accumulation and 
decreased mitochondrial SOD2 expression. Moreover, electron microscopy showed 
mitochondrial swelling (154). Vitamin K1 has been demonstrated as having 
antiproliferative and proapoptotic effects in colon cancer cell lines (155). 
Insulin stimulates the growth and proliferation of a variety of cells in culture. Several 
hypotheses have been proposed, including regulation of essential metabolic processes 
and interaction of insulin with receptors for insulin-like growth factors. Evidence 
supporting these various hypotheses is reviewed (156). 
Furthermore, it was demonstrated that pure albumin stimulates proximal tubular 
epithelial cells (PTEC) proliferation, and may have a role in homeostasis in health, as 
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well as in disrupted PTEC turnover in proteinuric nephropathies (157). Closely related 
results were obtained in our study when adding physiological concentration of albumin 
to the cell medium with plasma from cirrhotic patients, it was found a decrease in cell 
mortality respect the condition of low concentration of albumin. 
The lacking of activation of inflammasome in cells stimulated with plasma from 
patients was confirmed by gene expression. The same analysis was made in PBMC of 
patients and it was found an interesting expression pathway of TLR-2, that increase in 
PBMC of patients with acute decompensation and decrease in patients with acute-on-
chronic liver failure, respect a condition of compensated cirrhosis. Toll-like receptor 
(TLR) 2 was critically involved in production of TNF-α in response to Gram-positive 
microbial stimuli (158). Riondan et al. (159) showed an up-regulation of TLR-2 
expression in CD14+ PBMC of cirrhotic patients, despite none of whom showed 
evidence of overt infection. TLR-2 expression was increase irrespective of the etiology 
of cirrhosis and thus is likely related to cirrhosis per se. Following in vitro PBMC 
stimulation with an endotoxin of S. aureus, the production of TNF-α by was inversely 
related to PBMC expression of TLR-2 and was significantly blunted in cirrhotic patients 
compared with control subject. Riondan (159) concluded saying that, even in the 
absence of clinically apparent sepsis, PBMC of cirrhotic patients had been 
presensitized by exposure to Gram-positive bacteria antigens in vivo and developed 
tolerance to such antigens in vitro.  
The trouble of studying molecular signaling vehicled from the whole plasma led us to 
focus on one of its components, the EVs. These vesicles were one of the main actors 
responsible of cell-to-cell communication in the organism. In large scale, this 
communication led to both physiological and pathological crosstalk between distant 
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organs. The biogenesis and cellular release of the vesicles were largely described (160) 
and their involvement in liver disease pathogenesis was addressed through the 
characterization of extracellular vesicles in different scenario: nonalcoholic 
steatohepatitis, alcoholic hepatitis, viral hepatitis, liver fibrosis, cholangiopathies and 
hepatobiliary malignancies as reviewed elsewhere (160). Little is known about the 
characterization of EVs in the progression of liver pathology. In this project was 
observed that, after isolation from plasma, concentration of EVs increase with the 
progression of hepatopathy. Several works were published on changes in plasma levels 
of circulating EVs in patients with cardiovascular and other disease (69, 90, 91) or 
about the stimuli of EVs release relevant for liver disease (reviewed in (99) but in our 
case it was considered the increase in concentration related to hepatopathy stage by 
comparison between healthy subjects and patients and between compensated and 
decompensated cirrhosis, regardless of etiology of cirrhosis. About size of EVs Momen-
Heravi F. (161), according to Scott et al. (Analytical Ultracentrifugation: Techniques and 
Methods Scott et al., 2005 The Royal Society of Chemistry, 273–276), said that EVs 
derived from plasma and serum had smaller sizes that reflect more Brownian motion 
during sedimentation (streaming factor), which could lead to reduced resolution and 
sedimentation efficiency.  
Despite the vast majority of EVs were origined from platelets, those found in the 
cirrhotic patients were more frequently originated from activated endothelium. It 
could be hypothesized the use of a small number of markers for the characterization of 
platelets and monocyte origin. However, Stravitz et al. (127), in the characterization of 
EVs phenotypes in plasma of patients with acute liver failure and acute liver injury, 
reported the prevalence of platelets, hepatocyte, monocyte, but also endothelial cells, 
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although few in number. EVs isolated from patients expressed high levels of integrins 
and selectins molecules compare to healthy subjects. Surface-exposed receptors and 
ligands were responsible for biodistribution, for the binding of EVs to target cells or to 
the extracellular matrix. Subsequently, EVs may trigger intracellular signalling 
pathways through a simple interaction with the surface receptors or ligands of target 
cells or by undergoing internalization (55). 
While CD40L was classically described on the surface of activated T lymphocytes, it is 
also found on activated mast cells and eosinophils (162). An especially important site 
of CD40L expression is the activated platelet (163). Therefore, following an acute 
injury, infiltrating platelets and inflammatory cells can both activate a variety of local 
structural cells, including fibroblasts, through the CD40–CD40L system (164). This 
means two main things: the first, it could be hypothesized that EVs characterized in 
this study could have platelets phenotype, underlined by the CD40L in their surface. 
Secondly, Henn V. and colleagues in 1998 (163) demonstrated that CD40L on platelets 
induces endothelial cells to secrete chemokines and to express adhesion molecules, 
thereby generating signals for the recruitment and extravasation of leukocytes at the 
site of injury. In this case we could hypothesize that both platelets and platelets-
derived EVs may activated the endothelium in cirrhotic patients. Endothelium itself 
could release other EVs we described above. The result was a local injury and a spread 
of inflammatory molecules by EVs. While EVs in vitro effects were studied only on 
renal tubular cells, the results were very interesting: EVs from patients induced 
apoptotic death of cells that was significantly higher in acute decompensation and 
acute-on-chronic liver failure than that observed in compensated cirrhotic and healthy 
subjects. In the same times, a conspicuous production of ROS was induced which was 
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maximal in cells incubated with EVs from patients with acute decompensation and 
acute-on-chronic liver failure. The same cells showed substantially decreased in 
albumin uptake, that is one of the main function of renal epithelial tubular cells.  
Although albumin is a large anionic protein, it is not completely retained by the 
glomerular filtration barrier. In order to prevent proteinuria, albumin is reabsorbed 
along the proximal tubules by receptor-mediated endocytosis, which involves the 
binding proteins megalin and cubilin. Endocytosis depends on proper vesicle 
acidification. Disturbance of endosomal acidification or loss of the binding proteins 
leads to tubular proteinuria (165).  Interestingly an increase in albuminuria has been 
found in patients with cirrhosis and acute-on-chronic liver failure (166). Christensen et 
al. (167) claimed that megalin, a 517-kDa monomeric protein in the proximal tubular 
brush border, was responsible for albumin endocytosis, according to their functional 
data.  For this reason, also expression of megalin was investigated and it was shown 
that its expression did not change between the group of cells stimulated. Probably, EVs 
did not have effects on megalin production. EVs might have a role as inhibitory 
effector for albumin endocytosis but further experiments are needed. Mitochondria 
were essential in cells, especially if cells had active transport mechanism, such as 
Na+/K+ ATPase pump. In renal tubular cells stimulated with extracellular vesicles, was 
detected the concentration of PGC1α, a molecules involved in mitochondria biogenesis 
(168). The lacking of differences in PGC1α expression between the groups of cells 
treated suggested that EVs had no influences in mitochondria biogenesis. 
The zona occludens proteins (ZO) are a family of tight junction associated proteins that 
function as cross-linkers, anchoring the tight junction strand proteins to the actin-
based cytoskeleton (169). ZO-1 is a cell-intrinsic determinant of epithelial polarization 
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and lumen formation through coordination of multiple cellular processes, including 
mitotic spindle orientation (170). Physiological tubular handling of electrolytes is based 
on the maintenance of cell polarity and on the integrity of tight junction protein 
expression. After stimulation of tubular cells with healthy and cirrhotic groups EVs, it 
was observed a marked decrease of ZO-1 expression, especially between healthy 
subjects and patients with acute decompensation in cirrhosis. Other experiments are 
needed for confirm these data, but one may argue that these functional changes could 
alter the ability of tubular cells in maintaining compositionally distinct fluid-filled 
compartments with precise electrolyte concentrations. 
Increased permeability of the gut has been demonstrated in patients with 
inflammatory disorders such as cirrhosis (171) as well as animal models of intestinal 
inflammation and infection (172). Alterations in tight junction architecture are one 
cause of increased permeability (173). Changes in the expression of these different 
tight junction proteins alter the resistance of the intestinal barrier. Bacterial 
translocation commonly occurs in both cirrhotic rats with ascites (45–78%) and 
cirrhotic patients (174). In our study, only renal epithelial cell line were used and a 
decreased expression of ZO-1 was shown in renal tubular cells after EVs stimulation of 
cells. However, if we hypothesize a decrease expression of ZO-1 also in intestinal 
epithelium after EVs actions, we could consider that EVs may be involved in increasing 
intestinal permeability and bacterial translocation in cirrhotic patients.  
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Conclusions 
In conclusion, this study showed that characterization of inflammatory profile of 
patients with compensated, but especially decompensated cirrhosis, need a big sample 
size and well selected patients for avoid confounding factors and reach statistical 
significance. Sometimes, cytotoxic effect of plasma is not easy to detect if we consider 
the whole plasma. EVs may have active role in cirrhosis: they are able to induce 
apoptosis and increase ROS production in renal tubular cells. Furthermore, this study 
demonstrates that EVs from patients with decompensated cirrhosis and acute-on-
chronic liver failure are able to produce functional alteration of tubular epithelial cells 
such as the loss of cell polarity. We need to investigate the role of EVs in 
decompensated cirrhosis and study their hypothetic role as vehicle of mediator of 
extrahepatic organ injury and complications of cirrhosis.  
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